Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Ranging Studies of Oral Hymecromone
NCT02780752Phase 1Completed
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hymecromone in Respiratory Disease (RD) (3 arms). Primary endpoints: Change in sputum hyaluronan concentration at Day 4, Change in serum hyaluronan concentration at Day 4 and 1 more. Started Dec 2020; status: completed.
02
Drugs
hymecromone
03
Conditions
Respiratory Disease (RD)
Beyond the preview
Go deeper on NCT02780752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780752.